An Unusual Case of Allergic Reaction to Anakinra in a Patient with Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS) and Subsequent Canakinumab Treatment
Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is a rare hereditary systemic autoinflammatory disease (SAID). Treatment is based on corticosteroids, but often requires the addition of a biologic drug (anti-TNF agent, IL-1 receptor antagonist, etc) to achieve symptom contro...
Main Authors: | Marta Mejias Trueba, Marta Alonso Moreno, Noemi Garrido Puñal, Maria Soriano Martinez |
---|---|
Format: | Article |
Language: | English |
Published: |
SMC MEDIA SRL
2020-07-01
|
Series: | European Journal of Case Reports in Internal Medicine |
Subjects: | |
Online Access: | https://www.ejcrim.com/index.php/EJCRIM/article/view/1668 |
Similar Items
-
Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
by: Angel Luis Salcedo-Mingoarranz, et al.
Published: (2023-12-01) -
Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
by: Ali Şahin, et al.
Published: (2020-01-01) -
Subclinical TRAPS treated with canakinumab
by: M. Amatruda, et al.
Published: (2021-08-01) -
IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
by: Hana Malcova, et al.
Published: (2021-02-01) -
Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases
by: Riccardo Papa, et al.
Published: (2020-07-01)